Arm-specific versus total-sample fragility quotients in large vessel vasculitis trials
Gillette, J. J.; Lu, M.; Tsybulnik, D. Y.; Heston, T. F.
Show abstract
The fragility quotient normalizes the fragility index by total sample size but can obscure arm-specific fragility when trial arms are unequal, since the fragility index systematically alters outcomes in only one arm. We defined the modified-arm fragility quotient as the fragility index divided by the size of the arm in which outcomes are toggled. We compared it to the fragility quotient using three approaches: (1) re-analysis of 29 categorical outcomes from 18 large-vessel vasculitis trials (allocation ratios 1.0-2.0), (2) R grid simulation across 1:1 to 4:1 allocation ratios with sample sizes 60-240 (90,000 simulations), and (3) Python Monte Carlo simulation with 3,000 replications across 1:1, 1:2, and 1:3 allocations. In balanced 1:1 trials, the modified-arm fragility quotient equaled twice the fragility quotient exactly, as predicted. The proportion of trials in which the modified-arm fragility quotient exceeded twice the fragility quotient increased systematically with allocation imbalance: 0% (1:1), 81% (2:1), 93% (3:1), and 95% (4:1). In the R simulation, mean divergence between the modified-arm fragility quotient and twice the value of the fragility quotient increased from 0.00 (1:1) to 0.10 (4:1). Empirical data showed a strong correlation (r = 0.98) between the two quotients, but divergence increased in the 25 unbalanced allocation trials. The ratio of the modified-arm fragility quotient to twice the value of the fragility quotient scaled linearly with allocation ratio, with mean values of 1.0 (1:1), 1.36 (2:1), 1.91 (3:1), and 2.41 (4:1). These findings show that the modified-arm fragility quotient and total-sample fragility quotient convey equivalent information under equal allocation. In contrast, under unequal randomization, the total-sample fragility quotient can mischaracterize trial fragility due to dilution from the larger, unmodified arm, whereas the modified-arm fragility quotient avoids this bias by restricting normalization to the modified arm.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Approaches in Analyzing Predictors of Trial Failure: A Scoping Review and Meta-epidemiological study 95%
- Investigator-initiated versus industry-sponsored trials – Visibility and relevance of randomized controlled trials in clinical practice guidelines (IMPACT) 94%
- External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning 94%
Similar papers in this journal
- Using numerical modelling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample 96%
- Analysis of clinical trial registry entry histories using the novel R package cthist 94%
- Exploring scalable assessment methods for terminated trials in ClinicalTrials.gov: A cohort analysis of German and Californian trials 94%
Similar papers in this journal
- Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial 96%
- Trials that turn from retrospectively registered to prospectively registered: A cohort study of ‘retroactively prospective’ clinical trial registration using history data 95%
- Graphing and reporting heterogeneous treatment effects through reference classes 94%
Similar papers in this journal
- The use of the Registered Reports format for publication of randomized clinical trials: a cross-sectional study 94%
- Results reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed 94%
- Results dissemination from clinical trials conducted at German university medical centres was delayed and incomplete 93%
Similar papers in this journal
- Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: a scoping review 93%
- Use of estimands in cluster randomised trials: a review 93%
- Design and implementation of the multi-arm, multi-stage Therapeutics for Inpatients with COVID-19 (TICO) platform master protocol: An Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.